442,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Alberta Investment Management Corp

Key Points

• Alberta Investment Management Corp. acquired 442,000 Gilead shares during the second quarter, worth approximately $55.8 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above analyst expectations, driven by continued strength in its HIV franchise and PrEP products.
• The company declared a quarterly dividend of $0.82 per share, equal to a $3.28 annualized payout and a 2.4% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04, though some have lowered their targets and FY2026 earnings forecasts.

Alberta Investment Management Corp purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 442,000 shares of the biopharmaceutical company's stock, valued at approximately $55,842,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $2,617,152,000. Boston Partners acquired a new position in Gilead Sciences in the 4th quarter valued at about $517,808,000. Bank of America Corp DE raised its stake in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. Finally, Amundi lifted its position in Gilead Sciences by 25.5% during the 4th quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company's stock worth $1,168,501,000 after acquiring an additional 1,936,354 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $138.36 on Monday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a fifty day moving average price of $130.11 and a two-hundred day moving average price of $136.44. The stock has a market capitalization of $171.56 billion, a price-to-earnings ratio of -51.82 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio is presently -122.85%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Rothschild & Co Redburn lowered their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, May 19th. Barclays lowered their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 29th. Cantor Fitzgerald reissued an "overweight" rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $158.04.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source